Qvanteq AG
Surface technology to reduce thrombogenicity of medical devices.
Surface technology to reduce thrombogenicity of medical devices.
Qvanteq AG develops novel biofunctional surfaces to address and overcome the clinical adverse effects of today’s medical devices and vascular stents. Qvanteq’s Qstent technology stands for reduced thrombus formation and fast healing. Qvanteq AG was founded in early 2009 and is held by private investors. Qvanteq is ISO 13485 certified. Qvanteq is a spin-off company from the Swiss Federal Institute of Technology (ETH) Zurich. The company was awarded with the CTI start-up label in 2012.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | Fr.4.00M | - | 12 Feb 2013 | |
| Seed Round | Unknown | 1 |
|
27 Apr 2010 |
| Grant | Fr.10.00K | 1 |
|
08 Aug 2008 |
No recent news or press coverage available for Qvanteq AG.
We care about your data, and we'd love to use cookies make your experience better.
